Hillstream Biopharma (NASDAQ:CNTN) & Panbela Therapeutics (OTCMKTS:PBLA) Critical Comparison

Hillstream Biopharma (NASDAQ:CNTN) and Panbela Therapeutics (OTCMKTS:PBLA) are both manufacturing companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Volatility and Risk

Hillstream Biopharma has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 43.36, indicating that its stock price is 4,236% more volatile than the S&P 500.

Institutional and Insider Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Hillstream Biopharma and Panbela Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Panbela Therapeutics	0	0	0	0	0.00

Valuation & Earnings

This table compares Hillstream Biopharma and Panbela Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92 million	($3.99)	-0.94
Panbela Therapeutics	N/A	N/A	-$25.26 million	($71.13)	0.00

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hillstream Biopharma and Panbela Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-51.08%	-39.02%
Panbela Therapeutics	N/A	N/A	N/A

Summary

Panbela Therapeutics beats Hillstream Biopharma on 6 of the 9 factors compared between the two stocks.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.